Tumor-associated antigens in effusions of malignant and benign origin

[1]  Kyung-Hee Lee,et al.  Ascitic Fluid Analysis for the Differentiation of Malignancy-Related and Nonmalignant Ascites , 1999 .

[2]  A. Gerbes,et al.  Ascitic fluid analysis for the differentiation of malignancy‐related and nonmalignant ascites. Proposal of a diagnostic sequence , 1991, Cancer.

[3]  L. Abbott,et al.  Factors influencing the occurrence of vesicular-arbuscular mycorrhizas , 1991 .

[4]  A. Papadimitriou,et al.  Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  F. Guadagni,et al.  Ca 72‐4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers , 1990, International journal of cancer.

[6]  G. Krieger,et al.  ‘Mucin-Like Carcinoma-Associated Antigen’: Sensitivität und Spezifítät beim metastasierten Mammakarzinom , 1990 .

[7]  T. Kokubu,et al.  Discrimination of tuberculous from carcinomatous pleural effusion by biochemical markers: adenosine deaminase, lysozyme, fibronectin and carcinoembryonic antigen. , 1989, Japanese journal of medicine.

[8]  M. Nayar,et al.  Diagnostic value of carcinoembryonic antigen assay of pleural & peritoneal effusions in malignancy. , 1989, The Indian journal of medical research.

[9]  W. Wilmanns,et al.  Tumour associated antigens in diagnosis of serous effusions. , 1988, Journal of clinical pathology.

[10]  P. Cremaschi,et al.  Detection of malignant pleural effusions by tumor marker evaluation. , 1988, European journal of cancer & clinical oncology.

[11]  M. Klockars,et al.  The ovarian cancer associated antigen CA 125 in patients with pleural effusions. , 1988, European journal of cancer & clinical oncology.

[12]  S. Ichiyama,et al.  Diagnostic value of cancer antigen 15-3 (CA15-3) detected by monoclonal antibodies (115D8 and DF3) in exudative pleural effusions. , 1988, The European respiratory journal.

[13]  Y. Moriwaki,et al.  Tumor markers in pleural effusion diagnosis , 1988, Cancer.

[14]  D. Huhn,et al.  Prospektiver Vergleich der diagnostischen Wertigkeit von Zytologie und Immunzytologie bei thorakoskopisch-bioptisch untersuchten Pleuraergüssen , 1987, Klinische Wochenschrift.

[15]  D. A. Stein,et al.  Analysis of pleural effusions using automated flow cytometry , 1983, Cancer.

[16]  R. Bast,et al.  Tissue Distribution of a Coelomic- Epithelium‐Related Antigen Recognized by the Monoclonal Antibody OC125 , 1983, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[17]  A. Vladutiu,et al.  Differential diagnosis of pleural effusions: clinical usefulness of cell marker quantitation. , 1981, Chest.

[18]  F. Gudat,et al.  The immunohistochemical reactivity of a new anti-epithelial monoclonal antibody (MAb b-12) against breast carcinoma and other normal and neoplastic human tissues , 2004, Virchows Archiv A.

[19]  M. Ostrowski.  Intracavitary therapy with bleomycin for the treatment of malignant pleural effusions , 1989, Journal of surgical oncology. Supplement.

[20]  P. Pfitzer.  Pathologie und Zytologie maligner Ergüsse , 1988 .